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Objectives: Accumulating evidence suggested that dysregulation of cholesterol homeostasis might be a major
etiologic factor in initiating and promoting neurodegeneration in Alzheimer’s disease (AD). ATP-binding cassette
transporter A1 (ABCA1), hepatic lipase (HL, coding genes named LIPC) and cholesteryl ester transfer protein (CETP)
are important components of high-density lipoprotein (HDL) metabolism and reverse cholesterol transport (RCT)
implicated in atherosclerosis and neurodegenerative diseases. In the present study, we will investigate the possible
association of several common polymorphisms (ABCA1R219K, CETPTaqIB and LIPC-250 G/A) with susceptibility to
AD and plasma lipid levels.
Methods: Case–control study of 208 Han Chinese (104 AD patients and 104 non-demented controls) from
Changsha area in Hunan Province was performed using the PCR-RFLP analysis. Cognitive decline was assessed
using Mini Mental State Examination (MMSE) as a standardized method. Additionally, fasting lipid profile and the
cognitive testing scores including Wechsler Memory Scale (WMS) and Wisconsin Card Sorting Test (WCST) were
recorded.
Results and conclusions: We found significant differences among the genotype distributions of these three genes
in AD patients when compared with controls. But after adjusting other factors, multivariate logistic regression
analysis showed only ABCA1R219K (B = −0.903, P = 0.005, OR = 0.405, 95%CI:0.217-0.758) and LIPC-250 G/A variants
(B = −0.905, P = 0.018, OR = 0.405, 95%CI:0.191-0.858) were associated with decreased AD risk. There were
significantly higher levels of high-density lipoprotein cholesterol (HDL-C) and apolipoproteinA-I in the carriers of KK
genotype and K allele (P < 0.05), and B2B2 genotype of CETP Taq1B showed significant association with higher
HDL-C levels than other genotypes (F = 5.598, P = 0.004), while -250 G/A polymorphisms had no significant effect on
HDL-C. In total population, subjects carrying ABCA1219K allele or LIPC-250A allele obtained higher MMSE or WMS
scores than non-carriers, however, no significant association was observed in AD group or controls. Therefore, this
preliminary study showed that the gene variants of ABCA1R219K and LIPC-250 G/A might influence AD
susceptibility in South Chinese Han population, but the polymorphism of CETPTaq1B didn't show any association in
despite of being a significant determinant of HDL-C.
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Alzheimer' disease(AD) is one of the most common neu-
rodegenerative diseases which hallmark is the deposition
of amyloid-β (Aβ) in brain parenchyma and cerebral blood
vessels, accompanied by progressive cognitive decline.
However, detailed pathogentic mechanisms of AD remain
a matter of speculation. With the exception of age and
APOEε4 allele which is only one undisputed genetic com-
ponent identified [1,2], environmental risk profiles includ-
ing smoking, alcohol, obesity, hypertension, dislipidemia,
diabetes and cardiovascular diseases may be candidates
for AD [3-5]. Previous research has demonstrated that
cerebral atherosclerosis was strongly associated with an
increased frequency of neuritic plaques [6]. Moreover, the
association of some gene variation in lipid metabolism
with AD has been identified in a number of study [7,8]. So
the close links between vascular pathology and AD have
been payed more attention.
Accumulated evidence has shown that dysfunction of
cholesterol metabolism may contribute to cognitive
decline and AD [9], such as decreased high-density lipo-
protein cholesterol (HDL-C) levels [10,11], increased low-
density lipoprotein cholesterol (LDL-C) levels [4,12], and
decreased apolipoproteinA-I (apoA-I) levels [11,13]
known to be important risk factors for coronary athero-
sclerosis disease (CAD). The recent identification has been
extensively recognized that the effect of serum total chol-
esterol (TC) on dementia risk occurs in midlife but not
late-life, which may be different cardiovascular risk factor
profiles for AD [14,15]. In addition, intervention of
cholesterol-lowering drugs in some observational or co-
hort studies may decrease risk of developing dementia
[16] and delay the onset of AD in cognitively healthy eld-
erly individuals [17]. Growing evidence in previous animal
and cellular studies has also suggested that abnormalities
in cholesterol metabolism are important in the pathogen-
esis of AD, potentially by increasing neuronal content of
cholesterol, cleavage of the amyloid protein precursor
(APP), accumulation of Aβ peptide, neuroinflammation,
impairment in the cholinergic system and working mem-
ory [18-20]. However, the mechanisms are still ill-defined.
Recent work from Ghribi O and Marwarha G et al. indi-
cated that the oxidized cholesterol metabolite, 27-hydro-
xycholesterol, which had the ability to cross into the brain,
could increase Aβ levels and phosphorylated tau-protein
in adult rabbit brain slices [21,22], and the same result also
observed in cultured human neuroblastoma SH-SY5Ycells
[23]. Sharma S et al. found that hypercholesterolemia-
induced Aβ production in rabbit brain was associated with
alteration in IGF-1 signaling [24].
Many regulating genes affecting cholesterol or lipopro-
tein function have been implicated in the pathogenesis of
atherosclerosis diseases, especially reverse cholesterol
transport (RCT) mediated by HDL-C. HDL biogenesisoccurs through intergrated pathway that involves the lipid
transporter ABCA1 interacting with lipid-free apoA-I in
the initial steps, cholesteryl-ester transfer protein (CETP)
transferring cholesteryl-esters to VLDL/LDL by the LDL
receptor for eventual catabolism, lipoprotein lipase, hep-
atic lipase, and endothelial lipase contributing to the hy-
drolysis of phospholipids and residual triglycerides, and
phospholipid transfer protein transferring phospholipids
from VLDL/LDL to HDL, etc. [25]. ABCA1 is a trans-
membrane protein responsible for the efflux of cholesterol
and phospholipids to apolipoproteins such as apoA-I and
apoE [26], the gene mutations of which has been recog-
nized contributing to Tangier's disease and familial
hypoalphalipoproteinemia [27]. As known as common
polymorphisms in this gene could affect plasma HDL-C
levels and the risk of atherosclerosis and CAD [28-30],
dysregulation of ABCA1 expression may be a central me-
diator of AD neuropathology and dementia severity [31].
Several studies with AD mouse model revealed that
ABCA1 expression could regulate the level of apoE lipida-
tion and the production of Aβ [32-35]. But controversies
still remained [36,37]. One of the most studied ABCA1
variants is R219K (rs2230806) in exon region. Previous
researches indicated the common R219K variant was asso-
ciated with CSF cholesterol levels [38].
Hepatic lipase (HL) is a lipolytic enzyme, synthesized
by hepatocytes, not only participating in hydrolysis of
triglycerides and phospholipids of plasma HDL and
LDL, resulting in the formation of atherogenic small
dense LDL and HDL3-C particles [39], but also playing
an important role in RCT by its ability in the cellular
uptake of remnant lipoproteins as a ligand in the liver
[40]. CETP is a plasma glycoprotein that facilitates the
transferring of cholesterol esters, triglycerides and phos-
pholipids between plasma lipoproteins [41]. Common
genetic variants at both the CETP and LIPC loci have
been identified that may cause significant alterations in
HDL-C level and atherosclerosis, however, the findings
are still controversial in diverse racial groups [42-45].
The HL gene is located on chromosome 15 (q15–q22)
in humans [46]. Four common LIPC promoter variants
(−250 G/A, -514C/T, -710 T/C and -763A/G) which are
in almost complete linkage disequilibrium have been
widely studied [47]. The rare -250A and −514 T alleles
have been associated with low HL activity [48,49], buoy-
ant LDL particles [49], high triglyceride levels [50], high
HDL-C levels, and decreased risk of CAD [50-52]. One
of the most identified CETP variant is the TaqIB
(rs708272) in the first CETP intron [53]. The minor “B2”
allele (absence of the TaqIB restriction site) has been
associated with increased HDL-C levels and decreased
CETP activity [44].
As mentioned, abnormal lipid metabolism was consist-
ently indicated in the pathogenesis of AD, thereby, such
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dates for AD. In the past decade, the relationship be-
tween ABCA1R219K variants and risk of AD have been
reported in different regions and ethnic groups, however,
conflicting results were noted [38,54-58]. Polymorph-
isms in the CETP gene have been associated with lower
cardiovascular risk, but associations with memory de-
cline and dementia risk are unclear. Chen DW et al. in
Xuanwu Hospital of our country showed that there was
no significant difference of CETPTaq1B polymorphism
between AD and control groups regardless of APOE ε4
carrier status [59]. It also has been reported about the
association between several LIPC SNPs with the risk of
AD in two research [60,61], however, no significant dif-
ference was identified. Previously inconsistent results
have appeared in the literature, hence, the epistatic effect
of such variants on the risk profile associated with AD
remains to be elucidated.
Accordingly, in this study we will determine the rela-
tionship of polymorphisms in several common HDL-C-
related gene loci (ABCA1R219K, LIPC-250 G/A and
CETP Taq1B) with plasma lipids and the risk of AD in
Southern Chinese Han population.
Material and methods
Subjects
A total of 104 clinically diagnosed late-onset AD patients
and 104 controls without cognitive impairment were
randomly collected from a population of Chinese Han
nationality in Changsha area. Mini-mental state examin-
ation (MMSE) was used as the measure of cognitive
detecting and dementia severity [62]. All cases were
sporadic AD patients without relationships in Chinese
Han population of Hunan Province. Nobody had a fam-
ily history of dementia. All patients were clinically evalu-
ated and met the NINCDS/ADRDA criteria for diagnosed
probable AD [63]. There were 57 men and 47 women in
AD subjects, with an average age of 77.8±6.74 years and an
average age-at-onset of 72.9±7.29 years. During the
same period, all controls were recruited from old
people above 65 years in the same region, without cog-
nitive impairment and any severe nervous system dis-
eases and mental illnesses. There were 56 men and 48
women. The mean age was 76.5±6.14 years. Basic phys-
ical examination, Wechsler Memory Scale Test and
Wisconsin Cart Sorting Test were carried out for the
whole subjects. Everyone was interviewed for a detailed
inquiry including medical history, including family
history, education, smoke, alcohol, hyperlipidemia,
hypertension, diabetes and coronary heart disease, etc.
A venous fasting blood sample of 5 ml was obtained
from all subjects. The present study was carried out in
compliance with the Helsinki Declaration and was
approved by the Ethics Committee of the SecondXiangYa Hospital of Central South University. Written
informed consent was obtained from the patient for
publication of this report and any accompanying
images.Biochemical analysis
3 ml blood sample was used to determine serum lipid
levels. The levels of TC, TG, HDL-C, and LDL-C in
samples were determined by enzymatic methods, and
serum apoA-I and apoB levels by the immunoturbidi-
metric immunoassay. All determinations were per-
formed with an autoanalyzer in the Clinical Laboratory
Center of the Second XiangYa Hospital of Central South
University. According to NCEP-Adult Treatment Panel
III [64], lipid parameters of all subjects were stratified
presenting with appropriate HDL-C level (≥1.03 mmol/L
[40 mg/dL]) or low HDL-C (<1.03 mmol/L); appropriate
TC level (≤5.17 mmol/L[200 mg/dL]) or higher level
(>5.17 mmol/L); appropriate TG level (≤1.70 mmol/L
[150 mg/dL]) or higher level (>1.70 mmol/L); appropri-
ate LDL-C level (≤2.59 mmol/L[100 mg/dL]) or higher
level (>2.59 mmol/L).Genotying
The remaining 2 ml blood sample was used to extract
genomic DNA by phenol-chloroform methods. The iso-
lated DNA was stored at 4°C until analysis. All geno-
types had been examined using restriction fragment
length polymorphism (RFLP) amplified by polymerase
chain reaction (PCR). Information on polymorphic sites
of ABCA1, LIPC and CETP was from the database of
single nucleotide polymorphisms (SNPs) established by
the National Center for Biotechnology Information. The
ABCA1 R219K polymorphism was investigated by using
the following primers: 5'-GTA TTT TTG CAA GGC
TAC CAG TTA CAT TTG ACAA-3'(forward) and
5'-GAT TGG CTT CAG GAT GTCC-3'(reverse),
according to previous literure [65]. The detection of
genotypes was performed using 8% polyacrylamide gel
electrophoresis. The SNP rs2230806 predicts a non-
synonymous G to A exchange in exon 7 of ABCA1 gene
resulting in a R (Arg) to K (Lys) amino acid exchange at
position219. After digestion with EcoNI, three different
fragments: 177 bp or 107 ,70 bp were generated. For the
LIPC-250 G/A and CETP Taq1B polymorphisms, PCR
amplification was performed using 5'-GGCAAGGGCAT
CTTTGCTTC-3'(forward)/ 5'-GGTCGATTTACAGAAG
TGCTTC-3'(reverse) [66] and 5'-CACTAGCCCAGAG
AGAGGAGTGCC-3'(forward)/5'-CTGAGCCCAGCCGC
ACACTAA-3'(reverse) [67], respectively. The LIPC-250 G/
A products were 411, 301 and 110 bp or 301 and 110 bp or
411 bp by restriction enzyme DraI. The PCR amplification
of CETP Taq1B was catalyzed by TaqI to generate 535 bp,
Figure 2 Genotyping of PCR products of LIPC-250 G/A. Lane M,
100 bp Marker Ladder; Lanes 1/2/4/5/6, GA genotype (411 bp,
301 bp and 110 bp); Lane 3/8, GGgenotype (411 bp); and Lanes 7/9,
AA genotype (301 bp and 110 bp).
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(Figures 1, 2, 3).
Statistical analyses
Quantitative variables were expressed as mean±standard
deviation, and qualitative variables as percentages. First,
quantitative data was performed for normality test, if not,
transformed into natural logarithm profile. The compari-
son of quantitative traits, including biochemical index and
cognitive function scores (MMSE, WMS and WCST) be-
tween AD group and controls was carried out using
Independent-Samples t-Test. The effects of three SNPs on
serum lipid levels, the age-at-onset and cognitive function
scores were investigated by one-way ANOVA. Univariate
analysis of variance was applied to assess the interactive
effect of these gene variants on lipid profiles. Chi-square
(χ2) test was used to compare genotype and allele
frequency differences between AD cases and controls.
Standard goodness-of-fit test was used to test the Hardy-
Weinberg equilibrium. Multivariate logistic regression
analysis was done in order to evaluate the simultaneous
influence of these genetic variations and some environ-
mental factors on the risk of AD. The estimated odds
ratios (ORs) were adjusted for the effect of significant cov-
ariates, such as age, gender and education. All statistical
tests were two-sided. A P value of less than 0.05 was con-
sidered statistically significant. All statistical tests were
carried out using SPSS 13.0.
Results
General characteristics and serum lipid levels
There were no significant differences in age, gender and
education structure, systolic blood pressure, fasting
blood glucose, TG, LDL-C, apoA-I, apoB levels and the
percentages of history of smoking, alcohol, diabetes,Figure 1 Genotyping of PCR products of ABCA1R219K. Lane M,
100 bp Marker Ladder; Lanes 1/4/6, RK genotype (177 bp, 107 bp
and 70 bp); Lane 2/7/8, RR genotype (177 bp); and Lanes 3/5, KK
genotype (107 bp and 70 bp).hypertension and CAD between the two groups in the
present study (P > 0.05). The levels of diastolic blood
pressure and TC, the percentages of history of hyperlip-
idemia in AD group were higher than that in controls,
whereas HDL-C level was lower than that of controls
(P < 0.05) (Table 1).
Comparison of genotypes and alleles between cases and
controls
Three ABCA1R219K genotypes(RR, RK, KK), three
LIPC-250 G/A genotypes (GG, GA, AA) and CETP-
Taq1B genotypes (B1B1, B1B2, B2B2) were detected and
their genotype distributions in cases were consistent with
Hardy–Weinberg equilibrium (R219K, χ2 = 1.674, df = 2,
P = 0.433; LIPC-250 G/A, χ2 = 4.163, df = 2, P = 0.125;
CETPTaq1B, χ2 = 2.047, df = 2, P = 0.359), but in controls,
with the exception of ABCA1R219K (χ2 = 0.539, df = 2,
P = 0.764), the polymorphisms of -250 G/A and Taq1B
both departed from HWE.
ABCA1R219K: There was significant difference in the
frequencies of three genotypes between the AD patients
and controls (χ2 = 8.777, P = 0.012). The frequency of KKFigure 3 Genotyping of PCR products of CETPTaq1B. Lane M,
100 bp Marker Ladder; Lanes 1-4/6, B1B2 genotype (535 bp, 361 bp
and 174 bp); Lane 7/8/11, B1B1genotype (535 bp); and Lanes 5/9/10,
B2B2 genotype (361 bp and 174 bp).
Table 1 Comparison of general characteristics and serum lipids between AD patients and controls
Variable Cases Controls t-value or χ2 P
N 104 104
Age(years) 77.8±6.74 76.5±6.14 −1.495 0.137
Male/female 57/47 56/48 0.019 0.889
Systolic blood pressure(mmHg) 138.1±19.5 134.7±19.5 −1.239 0.217
Diastolic blood pressure(mmHg) 79.6±9.56 76.6±9.65 −2.256 0.025
Cigarette smoking[n(%)] 27(26.0) 40(38.8) 3.918 0.048
Alcohol consumption[n(%)] 8(7.7) 6(5.8) 0.286 0.593
History of hypertension[n(%)] 58(56.3) 64(64.6) 1.466 0.226
History of hyperlipidemia[n(%)] 44(42.3) 27(26.0) 6.180 0.013
History of diabetes[n(%)] 26(25.0) 15(15.2) 3.052 0.081
History of CHD[n(%)] 46(44.7) 41(41.4) 0.217 0.641
Education(proportion of high school and above level) 17(16.3) 36(34.6) 9.140 0.003
TG(mmol/L) 1.36±0.62 1.32±0.71 −0.909 0.364
TC(mmol/L) 4.48±0.89 4.10±1.04 −2.826 0.005
HDL-C(mmol/L) 1.33±0.31 1.44±0.31 2.450 0.015
LDL-C(mmol/L) 2.46±0.66 2.40±0.82 −0.848 0.397
ApoA-I(g/L) 1.17±0.28 1.21±0.22 1.162 0.247
ApoB(g/L) 0.79±0.22 0.80±0.22 0.089 0.929
TC, Total cholesterol; TG, Triglycerides; HDL-C, highdensity lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Apo, Apolipoproteins.
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controls (χ2 = 5.261, P = 0.022). The frequency of K allele
(KK + RK genotype) in AD patients was 54.8%, signifi-
cantly lower than that of controls (70.2%, P = 0.022). No
significant difference in R or K allele frequency was
found between the two groups (P > 0.05).
LIPC-250 G/A: Significant differences in the frequen-
cies of three genotypes (GG,GA and AA) between the
AD patients and controls were determined (χ2 = 7.925,
P = 0.019). The frequency of GG genotype in AD group
was obviously higher than that of controls (27.9%
&13.5%, χ2 = 5.233, P = 0.022). The frequency of GA +AA
genotype in AD patients was significantly lower than that
of controls (72.1%&86.5%, P = 0.016). There was no
significant difference in the frequency comparison of G
allele and A allele.
CETPTaq1B: The genotype distributions of the Taq1B
polymorphism in AD cases differed from that of controls
(χ2 = 8.102,P = 0.017). AD cases showed significantly
higher B1B1 genotype frequency compared to controls
(27.9% versus 14.4%; P = 0.035). No significant difference
between both groups was determined in allele frequen-
cies (P > 0.05). Distribution of all genotypes and alleles
were showed in Table 2.
SNPs and serum lipid levels
For the first time we performed genetic analysis of sev-
eral common polymorphisms of ABCA1, LIPC and
CETP in AD patients and control subjects for theassociation with serum lipid levels, and elucidated that
the important genetic factors could influence cholesterol
levels in our population. For ABCA1 R219K polymorph-
ism, there were significantly higher levels of HDL-C and
apoA-I in the carriers of KK genotype and K allele
(P < 0.05). During RR,RK,KK genotypes, the levels of
HDL-C and apoA-I significantly increased in ascending
order (P < 0.05), with TG level decreased but no statisti-
cally significance found (P > 0.05). We didn't found any
positive association between R219K SNP and plasma
levels of TC,LDL-C and apoB. In all serum lipids, only
apoA-I had been found distinct relevance with LIPC-
250 G/A. The level of apoA-I was highest in AA geno-
type, followed by GA and GG genotypes in total
subjects. The subjects carrying A allele had higher
plasma apoA-I level than non-carriers in both whole
population and the control group. Nevertheless, no
significant association was reached in our study for
serum HDL-C level with SNP of -250 G/A. In addition,
B2B2 genotype of CETP Taq1B showed significant asso-
ciation with higher plasma HDL-C levels than other gen-
otypes (F = 5.598, P = 0.004). After stratifying by gender,
this change was only found in females (F = 3.404, df = 2,
P = 0.038). And there was obviously lower HDL-C levels
in B1 allele carriers (1.24±0.35 mmol/L) than in non-
carriers (1.45±0.35 mmol/L, t = −2.463, P = 0.015) (Table 3).
We have further assessed the impact of the combined
effects of these frequent single-nucleotide polymorphisms
(SNPs) in the HDL catabolic pathway on the lipid levels.
Table 2 Genotype distribution and allele frequencies of these three polymorphisms (ABCA1R219K, LIPC-250 G/A and
CETP Taq1B) in cases and controls
Genotypes and alleles AD patients (n/%) Controls (n/%) χ2 P
ABCA1R219K
RR 47(45.2) 31(29.8) 3.282 0.070
RK 51(49.0) 56(53.8) 0.234 0.629
KK 6(5.8) 17(16.3) 5.261 0.022
χ2 = 8.777 P = 0.012
R/K(%) 70/30 57/43 3.646 0.056
LIPC-250 G/A
GG 29(27.9) 14(13.5) 5.233 0.022
GA 64(61.5) 82(78.8) 2.219 0.136
AA 11(10.6) 8(7.7) 0.474 0.491
χ2 = 7.925 P = 0.019
G/A(%) 59/41 53/47 0.731 0.393
CETP Taq1B
B1B1 14(13.5) 9(8.7) 1.087 0.297
B1B2 61(58.7) 80(76.9) 2.560 0.110
B2B2 29(27.9) 15(14.4) 4.455 0.035
χ2 = 8.102 P = 0.017
B1/B2(%) 57/43 53/47 0.323 0.570
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ABCA1 R219K and the LIPC-250 G/A polymorphisms on
HDL-C levels in total subjects: the carriers of the KK/AA
genotype showed the highest levels of HDL-C (2.07 +/−
0.11 mmol/L), whereas those carrying the RR/GG genotype
showed the lowest (1.07+/− 0.22 mmol/L) (Table 4). ThereTable 3 SNPs and serum lipid levels and age-on-set
Parameter ABCA1R219K





































































































aP < 0.05 in comparison with RR genotype, a*P < 0.01 in comparison with RR genoty
bP < 0.05 in comparison with GG genotype, b*P < 0.01 in comparison with GG genot
cP < 0.05 in comparison with B1B2 genotype, c*P < 0.01 in comparison with B1B2 ge
dP < 0.05 in comparison with B2B2 genotype.was no significant difference of HDL-C level among sub-
jects carrying CETP Taq1B genotypes with others.
SNPs and age-on-set and cognitive test scores
We examined the association of these polymorphisms
with age-on-set of AD cases, but found no significantLIPC-250 G/A CETP Taq1B































































































Table 4 Combination of ABCA1 R219K and LIPC -250 G/A
variants and serum HDL-C levels(mmol/L)
LIPC-250 G/A genotypes
GG GA AA
ABCA1 R219 K genotypes RR 1.07±0.22 1.33±0.82 1.19±0.26
RK 1.40±0.26 1.36±0.24 1.52±0.19
KK 2.02±0.66 1.70±0.40 2.07±0.11
F = 3.930 P = 0.004
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etic variations with quantitative measures of cognition
such as MMSE, WMS and WCST scores. In whole
population, subjects carrying ABCA1 219 K allele or
LIPC -250A allele obtained higher MMSE or WMS
scores than non-carriers, however, no significant associ-
ation was observed in AD group or controls. We didn't
find any effect of CETPTaq1B polymorphism on cogni-
tive test scores.Logistic regression analysis:risk factors for AD;
simultaneous effects of ABCA1,LIPC and CETP
Unconditional logistic regression analysis was done for
the assessment of the influence of age, gender, educa-
tion, TC, HDL-C and ABCA1, LIPC, CETP minor
alleles, and the interaction terms (ABCA1 × LIPC ×
CETP) on the risk for developing AD. The analyses
revealed no significant influences of CETPTaq1B poly-
morphism, TC and HDL-C on the risk of AD. It was evi-
dent that, while there was no obvious interaction, both
minor alleles (ABCA1 and LIPC) had statistically significant
independent effects on AD risk (P= 0.005, OR= 0.405, 95%
CI:0.217-0.758 and P= 0.018, OR= 0.405, 95%CI:0.191-
0.858, respectively). Moreover, it was also suggested that age
(P= 0.003, OR = 2.620, 95%CI:1.381-4.972) and levels of
education(B =−1.052, adjustedOR= 0.349, P = 0.004, 95%
CI:0.172-0.710) had an independent significant association
with AD respectively. The final model is shown in Table 5.Discussion
Alzheimer's disease is a multifactorial disease but its
aetiology and pathophisiology still has not been fully
understood. Similar to most complex diseases, AD is
likely to be influenced not only by genetic factors, but
also by environmental components. One environmentalTable 5 Logistic regression analysis:risk factors for AD
Variable B P OR 95%CI
age 0.963 0.003 2.620 1.381-4.972
education −1.052 0.004 0.349 0.172-0.710
219K allele −0.903 0.005 0.405 0.217-0.758
−250A allele −0.905 0.018 0.405 0.191-0.858factor which role in AD pathogenesis remains controver-
sial based on systematic review of case–control and co-
hort studies is dyshomeostasis of cholesterol [9]. It is
well known that dyslipidaemia is a complex trait caused
by multiple environmental and genetic factors and their
interactions. This study aimed to investigate variations
of several cholesterol-related genes and correlation to
serum lipid levels and risk of LOAD in Chinese South-
ern Han population in Hunan Province.
The relationship between cholesterol levels in plasma
and risk of AD has been still a matter of discussion. In our
study, the level of TC in AD patients was higher than that
in controls (P < 0.01), whereas HDL-C level lower than
that in controls (P < 0.05), in line with previous studies in-
dicating lower plasma HDL-C levels, higher LDL-C levels,
or increased TC level in AD cases when compared to con-
trols [11,68,69]. But after adjusting other factors in logistic
regression analysis we didn't find any potential association
of serum TC or HDL-C with risk of AD. Hall K et al. [12]
and Helzner EP [4] et al. respectively had reported an ob-
vious association of plasma TC or LDL-C levels with
increased risk of LOAD and the rate of cognitive decline
in the eldly, but the former result only for carriers without
APOEε4 [12]; Recently higher HDL-C level (>55 mg/dL)
was demonstrated with lower risk for AD in a large pro-
spective cohort study carried out in 1130 cognitively intact
old people by Reitz C et al. [10]. However, this was contra-
dicted by some studies demonstrating increased choles-
terol level was linked to reduced AD risk [70,71].
Furthermore, high midlife TC, not late-life TC, was asso-
ciated with increased risk of AD and cognitive decline,
that was supported by a systematic review of prospective
studies with meta-analysis [14]. It remained controversial
due to ethnic or region specificity, carrying apoEε4 allele
or not, difference of life styles such as fat intake and BMI
[72,73], physical activity and oxidative stress, as well as
homocysteine by likely impairing apoE3 function for HDL
[74]. It was reported that using some drugs might produce
any uncertain effects, for example, taking statins could
slow the rate of cognitive decline and delay the onset of
AD and reduce risk of dementia in the eldly [17,75], and
donepezil hydrochloride using for AD patients may cause
up-alteration of serum TG,TC and LDL-C [76]. These fac-
tors may be of equal importance when considering AD
risk. Although numerous hypotheses have been advanced
to explain the role of cholesterol in the pathogenesis, it
remained to be elucidated. Currently, it has been exten-
sively recognized that cholesterol may be associated
closely with brain Aβ levels. Animal studies showed that
hypercholesterolemia may lead to increase brain Aβ levels
[20]. Recent convincing evidence by Lesser et al. per-
formed in 281 AD patients indicated that serum TC and
LDL levels were clearly positively correlated with densities
of neuritic plaques in both neocortex and hippocampal
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results in a decreased risk of LOAD would strengthen
these findings.
In this pilot study we determined an apparent associ-
ation between the polymorphism of ABCA1 R219K and
AD. The frequencies of carrying both KK genotype and
K allele in AD group were obviously lower than that of
controls (χ2 = 5.261, P = 0.022), and logistic regression
analysis showed that K allele may be an independent
protective factor for AD (P = 0.005, OR = 0.405, 95%
CI:0.217-0.758), consistent with previous report by
Wang F et al. that risk of AD was significantly decreased
in K allele or KK homozygote carriers compared with
RR genotypes carriers [57]. Nevertheless, some studies
in other populations have excluded the association of
ABCA1 gene with LOAD [38,78], while others have
shown an increased risk of AD for female 219 K allele
carriers [56]. Important differences in the population
sizes, genetic composition, and background environment
of the populations studied such as diets may be partly
responsible for mutative AD susceptibility and these dis-
cordant results. The minor allele frequency of R219K
was reported 25% in Caucasian populations [79], 46% in
Europeans [65]. In addition, we didn't find any correl-
ation with age-on-set of AD, however, Wollmer MA
et al. once reported that A allele was associated with
delayed age-at-onset by 1.7 years on average [38].
Mechanisms via which this polymorphism could affect
pathogenesis of AD remain to be elucidated. Some studies
focused on pathological mechanism have suggested that
ABCA1 mRNA expression was significantly elevated at
the earliest stage of dementia, and positively correlated
with neuropathological stages and neuritic plaque density
counts and dementia severity, through comparison of
postmortem hippocampus from persons at different stages
of AD and cognitively intact normal donors by Akram A
et al. [31]. And transgenic animal models have repeatedly
shown the influence of loss of ABCA1 on apoE lipidation,
Aβ production or deposition and cognitive impairment
[80]. Secondly, ABCA1 gene is located on 9q31.1, just
closing to susceptible loci region of LOAD oncome [81].
Furthermore, K allele may produce a benefit profile of
serum lipids [82]. Therefore, it is also understandable that
carrying K allele may be correlated with protecting from
AD. However, much larger sample would be needed to
confirm such an interaction.
ABCA1 is a member of a superfamily of membrane pro-
teins as a key enzyme in regulating plasma HDL-C and
apoA-I metabolism [83]. Many conflicting results from pre-
vious studies have evaluated the associations of R219K poly-
morphism with level of HDL-C and risk of developing CAD
[82,84,85]. However, little work about the association of this
genetic variation with plasma lipids in AD patients has been
assessed. In this pilot study, we first reported the associationof R219K gene variants with lipids in AD patients, suggest-
ing the possible involvement of cholesterol with AD. There
was significantly higher levels of HDL-C and apoA-I in the
carriers of KK genotype and K allele (P < 0.05) in either AD
patients or controls, similar to several previous findings
[82,86,87]. Recent meta-analysis using thousands of samples
established that this association only presented in Asian, not
in White populations [82,86]. Genvigir FD et al. determined
that K allele was correlated with higher apoA-I level in
Brazilian individuals [88]. However, other studies failed to
find any significant influence of R219K variation on HDL-C
or other lipid parameters levels [85,89-91]. The explanation
for these contradictory findings has been set on not only the
limited effects of gene variation but gene-environment inter-
actions. Different populations have discrepant HDL-C levels,
such as relatively lower in Turks [92]. KK genotype of
ABCA1R219K polymorphisms has been reported linked to
a 5.5% higher concentration of small HDL particles [93].
Moreover, controversial conclusion may vary with other fac-
tors such as age [94], gender [95], smoking [96], obesity [97]
and existing linkage disequilibrium or interactive effect with
other candidate genes [98]. In addition, the influence of
ABCA1 gene variants on other lipid molecules and enzymes
secondarily can mildly influence HDL concentration. Clee
SM, Pasdar A and Li J et al. reported downward trend of
TG level during RR,RK,KK genotypes and 219 K allele
carriers [65,99,100]. This trend was replicated in our popula-
tion, but no statistically significance found. Further investi-
gations are needed to prove the influence of ABCA1
polymorphisms on serum lipid levels and to determine
whether it could be a genetic determinant of AD.
Previous studies have shown that the A allele of the
LIPC-250 G/A and the B1 allele of Taq1B in the intron re-
gion of CETP were associated with decrease in HL activity
and CETP activity and elevation of HDL-C levels [49,101].
The present study first revealed the association of -250 G/
A variants with plasma lipids in AD patients in the Chinese
population, only finding an significant effect on serum
apoA-I levels, which was higher in the subjects carrying A
allele or AA genotype than other genotypes or alleles car-
riers in total subjects and the control group. It was similar
to the previous research studied in type2 diabetes and CAD
patients by Wei M et al. [52]. Nevertheless, we found no
significant effect on HDL-C and other lipoprotein levels.
To date, there has been considerable evidence about
-250 G/A variant and plasma lipoprotein concentrations,
but the result remains inconsistent [52,102-104]. Influence
of gender-specificity on the association was found in some
studies [51,103,104]. Transgenic mice studies has demon-
strated that overexpression of HL has led to a marked re-
duction in plasma HDL-C [105], however, there have
existed many contradictory results in clinical epidemio-
logical studies, which may be attributed to various factors,
such as (i)restriction in terms of sample size and ethnic
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isms of genes, for instance, Wood KC et al. indicated inter-
actions during LIPC-514C/T and LIPC-250 G/A and apoE
gene polymorphisms could distinctly influence serum lipid
profiles [106]; (iii)both having pro-atherogenic and anti-
atherogenetic properties for HL [107,108]; (iv)related to
HDL subclasses, mainly as HDL2-C [49], etc. The propor-
tion of variation in HDL-C attributable to polymorphisms
within the HL gene is probably no more than 25% [40,109].
However, it is not clear whether the promoter polymorph-
isms was functional or merely a marker of another physio-
logical polymorphism located elsewhere, because of
complete linkage disequilibrium [47].
CETP has its capacity to mediate transferring of neutral
lipids among the lipoproteins by reversely exchanging tri-
glycerides and cholesteryl ester between TG-rich lipopro-
teins and HDL, producing HDL with reduced cholesteryl
ester and increased TG [110]. Most previous studies
examining the relationship between CETP variants and
plasma HDL-C levels and CAD risk have focused on the
intronic Taq1B variant [101]. Our research first indicated
that B2B2 genotype was significantly associated with higher
plasma HDL-C levels than other genotypes, and HDL-C
levels in B1 allele carriers (1.24±0.35 mmol/L) was obvi-
ously lower than that in non-carriers (1.45±0.35 mmol/L,
P = 0.015) in AD patients, supporting previous and recent
studies in which homozygous minor allele genotypes or
B2 allele would be associated with highest HDL-C con-
centrations [43,44,98,111]. However, there also have
been addressed no distinct anti-atherogenic potential of
this polymorphism in some studies [102,112]. It may be
due to diverse genotype or allele frequencies in different
racial and regional groups. The meta-analyse in 2008
suggested the minor allele (B2 allele) frequency in the
Whites was the same as East Asian populations (0.42)
[101], in accordance with 0.43 and 0.47 respectively in
our AD participants and controls. We also found the
effect of B2 allele or homozygous genotype on HDL-C
more apparent in females, which was probably associated
with modification of hormone in menopausal status [113].
Such genetic testing is limited by the fact that each
sequence variant explains only a modest fraction of the
variance (2% or less) in lipid levels [114]. However, the
combination of several lipid-related polymorphisms per-
haps could improve risk prediction.
CETP-mediated triglyceride enrichment of HDL-C not-
ably increases the ability of hepatic lipase to assemble
HDL-C [41]. So the potential interaction between LIPC
and CETP variants on lipid levels needed to be elucidated.
But our study indicated that there was no significant effect
of combinations of CETPTaqIB and LIPC -250 G/A or
ABCA1 R219Kvariants on plasma HDL-C levels and other
lipids. We found a significant interaction of ABCA1
R219K and LIPC-250 G/A polymorphisms on HDL-Clevels in the total subjects (F = 3.930, P = 0.004). Previous
studies have shown that combinations of minor variants
in these common polymorphisms could produce more
pronounced effect on serum lipids [43,98,115]. However,
recently a large cardiovascular cohort by Kathiresan et al.
suggested that combinations of common SNPs only
showed a weak association with alteration in HDL-C level
[116]. The determinants of HDL-C levels are involved in
not only gene variants, but also many environmental pro-
files. Approximately 50% of the inter-individual variation
in serum HDL-C levels was considered to be genetically
determined [117]. In addition, age, diet, smoking, alcohol,
body mass index (BMI), physical activity [118] and differ-
ent levels and distribution of HDL subclasses all play a
role in determining individual HDL-C levels. CETP and
HL are implicated in the metabolism of plasma lipopro-
teins, but the effects of CETP and LIPC genotypes on ath-
erosclerosis may be dependent on LDL-receptor activity
[119]. The relationship between HDL and these gene var-
iants needs to be validated in a larger longitudinal study.
In the past decade, while a number of case–control
studies have been carried out to investigate the relation-
ships between LIPC or CETP polymorphisms and risk of
atherosclerosis diseases [43,51,52,101,115], little is
known about their effect on neurodegenerative disease.
In 2008 Haiyan Zhu et al. has detected three LIPC SNPs
(rs6083,rs6084 and rs6074 in coding region) in three
LOAD series, and recently in a German case–control
sample (438 AD patients and 290 controls) Laws SM
et al. also evaluated 25 single nucleotide polymorphisms
(−250 G/A not included), however, no association with
AD was found [60,61]. Our study first showed that
-250 G/A variant may decrease the risk of AD after
adjusting other factors like gender, age and education for
logistic regression analysis. The independent protective
effect of A allele may be understandable due to its impli-
cation in lipid metabolism involved in decreasing plasma
HL activity, elevating HDL-C and apoA-I levels. There
was significant difference in the A allele frequency in dif-
ferent regions and populations: 0.21 in American Cauca-
sian, 0.47 and 0.45 in Japanese Americans and African
Americans respectively [42,49], 0.63 in Korean [42] and
0.32 in Southern Brazilian population [51]. Moreover,
the influences of APOEε4 and other genes cholesterol-
related need to be taked into account.
Earlier research showed that in AD tissue CETP was ex-
tensively expressed in the astrocytes of gray matter as well
as the white matter [120], so alteration of CETP activity
might play a role for AD pathology. Several studies have
showed CETP gene variants such as I405V,D442G may
have a potential association with memory decline and de-
mentia risk [59,121,122]. But others didn't find any positive
results [123,124]. For TaqIB polymorphism, subsequent
studies reported no statistically significant differences with
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CETP TaqIB and AD [125]. And the same results main-
tained in the study of Xuanwu Hospital of our country by
Chen DW et al. regardless of APOE ε4 carrier status [59].
We also didn't find any correlation between TaqIB variation
and AD risk in Hunan Han population, though AD cases
showed significantly higher B1B1 genotype frequency com-
pared to controls (27.9% versus 14.4%; P = 0.035). Further
studies combined with multi-ethnic research are warranted
to determine the value of CETP variants for AD.
We further investigated interactive effect among these
ABCA1 and LIPC and CETP variants on the risk of AD.
These variants, which could decrease protein activity
and increase HDL-C levels, should, in theory, decrease
atherosclerosis and reduce the incidence of AD. How-
ever, in our case–control study, on adjusting for age, sex
and education, logistic regression analysis revealed no
statistically significant interaction.
In this pilot study, we first determined the association of
these genetic variations with quantitative measures of cogni-
tion such as MMSE, WMS and WCST scores. The former
two ones were used to examine the degree of memory im-
pairment, and WCST implicated in evaluation of frontal be-
havioral function. ABCA1219K allele and LIPC-250A allele
carriers were associated with higher MMSE or WMS scores
in total sample, however, no significant difference was
observed in AD patients or controls. This was in line with
indication in logistic regression. This protective effect may
be attributed to the beneficial effect of the ABCA1219K and
LIPC-250A alleles on HDL-C. Pathological mechanism
studies suggested ABCA1mRNA expression was positively
correlated with Braak neuropathological stages and demen-
tia severity [31]. And Hirsch-Reinshagen et al. has found
that increased ABCA1 expression may result in improved
cognition in amyloid mouse models [80]. However, there
was no significant association of ABCA1 gene variants with
MMSE scores in the literature [56]. Replication with a larger
sample size and in other ethnic groups and standardization
of test process is warranted.
Many environmental vascular risk factors such as age,
smoking, obesity, abnormal lipid metabolism, physical
inactivity and diabetes are thought to be necessary co-
contributors or initiators of the disease process. We
didn't find smoking, alcohol and diabetes had any dis-
tinct effect on AD incidence as well as sex. However,
some studies have suggested female gender was asso-
ciated with an increased risk of AD [78,126]. Age did
not significantly influence the risk of AD in the study
consisted of 241 German AD patients and 294 non-
demented controls by Kölsch H et al. [78].
Currently, while the effect of education on the incidence
of dementia and AD has not been stated universally, major
studies reported to date as well as our finding have showed
that higher education might shorten cognitive impairmentand decrease AD risk. We found higher education may be
an independent protective determinant of AD, in accord-
ance with the results in previous studies and the recent
Epidemiological Clinicopathological Studies in Europe
(EClipSE) that longer years in education were associated
with decreased dementia risk and low educational attain-
ment was associated with a higher risk of AD [126-128].
Reuser M et al. also found that higher education may delay
incidence of cognitive decline and protect against cognitive
impairment between age 55 and 75 by assessment in three
ethnic groups in the US Health and Retirement Study [129].
But adjusting for age the Framingham Study by Cobb JLet al
showed low educational attainment was not a risk factor for
AD compared with those who earned a high school diploma
(relative risk:1.04, 95% CI:0.62 to 1.74) [130]. Further investi-
gations are needed to prove the influence of education on
risk of AD in Chinese Han population.
Conclusion
In summary, for the first time we reported a significant
association of the ABCA1 R219K and LIPC-250A poly-
morphisms with sporadic AD risk and cognitive and me-
morial scores in Southern Chinese Han population, but
no pronounced effect in CETP TaqIB SNP. We also pro-
vided preliminary evidence for the first time that these
three variations were associated with serum lipids in AD
patients. Hence, the combined study of common genetic
variants as well as environmental risk factors, may con-
tribute to the etiological understanding of the remaining
fraction unexplained in AD. Replication with a larger
sample size, more detailed individual information and
more rare loci variants as well as other ethnic groups is
warranted.
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